Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

{ 'indexed': { 'date-parts': [[2022, 12, 17]], 'date-time': '2022-12-17T10:50:25Z', 'timestamp': 1671274225430}, 'reference-count': 23, 'publisher': 'European Respiratory Society (ERS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 8, 26]], 'date-time': '2021-08-26T00:00:00Z', 'timestamp': 1629936000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100003130', 'name': 'Fonds Wetenschappelijk Onderzoek', 'doi-asserted-by': 'publisher', 'award': ['1843118N']}, { 'DOI': '10.13039/501100019353', 'name': 'Belgian Health Care Knowledge Centre', 'doi-asserted-by': 'crossref'}], 'content-domain': {'domain': ['ersjournals.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 2]]}, 'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>Several randomised clinical trials have ' 'studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different ' 'protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ' 'neutralising antibody titres, at different time-points and severities of ' 'illness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In the ' 'prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were ' 'randomised to 4\u2005units of open-label convalescent plasma combined with standard of care ' '(intervention group) or standard of care alone (control group). Plasma from donors with ' 'neutralising antibody titres (50% neutralisation titre (NT<jats:sub>50</jats:sub>)) ≥1/320 ' 'was the product of choice for the ' 'study.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Between 2 May ' '2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 ' 'patients to the control group according to a 2:1 allocation scheme. A median (interquartile ' 'range) volume of 884 (806–906)\u2005mL) convalescent plasma was administered and 80.68% of ' 'the units came from donors with neutralising antibody titres (NT<jats:sub>50</jats:sub>) ' '≥1/320. Median time from onset of symptoms to randomisation was 7\u2005days. The proportion ' 'of patients alive and free of mechanical ventilation on day 15 was not different between both ' 'groups (convalescent plasma 83.74% (n=267) <jats:italic>versus</jats:italic> control 84.05% ' '(n=137)) (OR 0.99, 95% CI 0.59–1.66; p=0.9772). The intervention did not change the natural ' 'course of antibody titres. The number of serious or severe adverse events was similar in both ' 'study arms and transfusion-related side-effects were reported in 19 out of 320 patients in ' 'the intervention group ' '(5.94%).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Transfusion ' 'of 4\u2005units of convalescent plasma with high neutralising antibody titres early in ' 'hospitalised COVID-19 patients did not result in a significant improvement of clinical status ' 'or reduced mortality.</jats:p></jats:sec>', 'DOI': '10.1183/13993003.01724-2021', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 26]], 'date-time': '2021-08-26T16:16:09Z', 'timestamp': 1629994569000}, 'page': '2101724', 'update-policy': 'http://dx.doi.org/10.1183/ers-crossmark-policy', 'source': 'Crossref', 'is-referenced-by-count': 25, 'title': 'Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma', 'prefix': '10.1183', 'volume': '59', 'author': [ {'given': 'Timothy', 'family': 'Devos', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3260-280X', 'authenticated-orcid': False, 'given': 'Quentin', 'family': 'Van Thillo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Veerle', 'family': 'Compernolle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tomé', 'family': 'Najdovski', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marta', 'family': 'Romano', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7697-6849', 'authenticated-orcid': False, 'given': 'Nicolas', 'family': 'Dauby', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laurent', 'family': 'Jadot', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mathias', 'family': 'Leys', 'sequence': 'additional', 'affiliation': []}, {'given': 'Evelyne', 'family': 'Maillart', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarah', 'family': 'Loof', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lucie', 'family': 'Seyler', 'sequence': 'additional', 'affiliation': []}, {'given': 'Martial', 'family': 'Moonen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michel', 'family': 'Moutschen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Niels', 'family': 'Van Regenmortel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin K.', 'family': 'Ariën', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cyril', 'family': 'Barbezange', 'sequence': 'additional', 'affiliation': []}, {'given': 'Albrecht', 'family': 'Betrains', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mutien', 'family': 'Garigliany', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthias M.', 'family': 'Engelen', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4068-7228', 'authenticated-orcid': False, 'given': 'Iwein', 'family': 'Gyselinck', 'sequence': 'additional', 'affiliation': []}, {'given': 'Piet', 'family': 'Maes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexander', 'family': 'Schauwvlieghe', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5616-8548', 'authenticated-orcid': False, 'given': 'Laurens', 'family': 'Liesenborghs', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ann', 'family': 'Belmans', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8698-2858', 'authenticated-orcid': False, 'given': 'Peter', 'family': 'Verhamme', 'sequence': 'additional', 'affiliation': []}, {'given': 'Geert', 'family': 'Meyfroidt', 'sequence': 'additional', 'affiliation': []}], 'member': '81', 'published-online': {'date-parts': [[2021, 8, 26]]}, 'reference': [ { 'key': '2022021001300748000_59.2.2101724.1', 'unstructured': 'World Health Organization . WHO coronavirus (COVID-19) dashboard with ' 'vaccination data. 2021. https://covid19.who.int Date last accessed: 16 ' 'July 2021.'}, { 'key': '2022021001300748000_59.2.2101724.2', 'doi-asserted-by': 'crossref', 'first-page': '1545', 'DOI': '10.1001/jama.2020.4031', 'article-title': 'Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: ' 'early experience and forecast during an emergency response', 'volume': '323', 'author': 'Grasselli', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '2022021001300748000_59.2.2101724.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30243-7'}, { 'key': '2022021001300748000_59.2.2101724.4', 'doi-asserted-by': 'crossref', 'first-page': '100019', 'DOI': '10.1016/j.lanepe.2020.100019', 'article-title': 'The role of organizational characteristics on the outcome of COVID-19 ' 'patients admitted to the ICU in Belgium', 'volume': '2', 'author': 'Taccone', 'year': '2021', 'journal-title': 'Lancet Reg Health Eur'}, { 'key': '2022021001300748000_59.2.2101724.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'}, { 'key': '2022021001300748000_59.2.2101724.6', 'first-page': '1491', 'article-title': 'Interleukin-6 receptor antagonists in critically ill patients with ' 'Covid-19', 'volume': '84', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2022021001300748000_59.2.2101724.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2030340'}, { 'key': '2022021001300748000_59.2.2101724.8', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/nejmoa2101643'}, { 'key': '2022021001300748000_59.2.2101724.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': '2022021001300748000_59.2.2101724.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2023184'}, { 'key': '2022021001300748000_59.2.2101724.11', 'doi-asserted-by': 'crossref', 'first-page': '917.e1', 'DOI': '10.1016/j.cmi.2021.02.029', 'article-title': 'A real-life setting evaluation of the effect of remdesivir on viral ' 'load in COVID-19 patients admitted to a large tertiary centre in Israel', 'volume': '27', 'author': 'Goldberg', 'year': '2021', 'journal-title': 'Clin Microbiol Infect'}, { 'key': '2022021001300748000_59.2.2101724.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m3939'}, { 'key': '2022021001300748000_59.2.2101724.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2031304'}, { 'key': '2022021001300748000_59.2.2101724.14', 'doi-asserted-by': 'crossref', 'first-page': '3189', 'DOI': '10.1038/s41467-021-23469-2', 'article-title': 'Effects of potent neutralizing antibodies from convalescent plasma in ' 'patients hospitalized for severe SARS-CoV-2 infection', 'volume': '12', 'author': 'Gharbharan', 'year': '2020', 'journal-title': 'Nat Commun'}, { 'key': '2022021001300748000_59.2.2101724.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2033700'}, { 'key': '2022021001300748000_59.2.2101724.16', 'doi-asserted-by': 'crossref', 'first-page': '1185', 'DOI': '10.1001/jama.2021.2747', 'article-title': 'Association of convalescent plasma treatment with clinical outcomes in ' 'patients with COVID-19: a systematic review and meta-analysis', 'volume': '325', 'author': 'Janiaud', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '2022021001300748000_59.2.2101724.17', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2031893'}, { 'key': '2022021001300748000_59.2.2101724.18', 'doi-asserted-by': 'crossref', 'first-page': '981', 'DOI': '10.1186/s13063-020-04876-0', 'article-title': 'A randomized, multicentre, open-label phase II proof-of-concept trial ' 'investigating the clinical efficacy and safety of the addition of ' 'convalescent plasma to the standard of care in patients hospitalized ' 'with COVID-19: the Donated Antibodies Working against nCoV ' '(DAWn-Plasma) trial', 'volume': '21', 'author': 'Devos', 'year': '2020', 'journal-title': 'Trials'}, { 'key': '2022021001300748000_59.2.2101724.19', 'doi-asserted-by': 'publisher', 'DOI': '10.2307/2291635'}, { 'key': '2022021001300748000_59.2.2101724.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0140-6736(21)00897-7'}, { 'key': '2022021001300748000_59.2.2101724.21', 'doi-asserted-by': 'crossref', 'first-page': 'e150646', 'DOI': '10.1172/JCI150646', 'article-title': 'A randomized double-blind controlled trial of convalescent plasma in ' 'adults with severe COVID-19', 'volume': '131', 'author': "O'Donnell", 'year': '2021', 'journal-title': 'J Clin Invest'}, { 'key': '2022021001300748000_59.2.2101724.22', 'doi-asserted-by': 'crossref', 'first-page': '1100', 'DOI': '10.1111/bjh.17266', 'article-title': 'Convalescent plasma treatment of persistent severe acute respiratory ' 'syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma ' 'with impaired humoral immunity and lack of neutralising antibodies', 'volume': '192', 'author': 'Betrains', 'year': '2021', 'journal-title': 'Br J Haematol'}, { 'key': '2022021001300748000_59.2.2101724.23', 'doi-asserted-by': 'crossref', 'first-page': '2290', 'DOI': '10.1182/blood.2020008423', 'article-title': 'Convalescent plasma therapy for B-cell-depleted patients with ' 'protracted COVID-19', 'volume': '136', 'author': 'Hueso', 'year': '2020', 'journal-title': 'Blood'}], 'container-title': 'European Respiratory Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1183/13993003.01724-2021', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 10]], 'date-time': '2022-02-10T09:30:34Z', 'timestamp': 1644485434000}, 'score': 1, 'resource': {'primary': {'URL': 'http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01724-2021'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8, 26]]}, 'references-count': 23, 'journal-issue': { 'issue': '2', 'published-online': {'date-parts': [[2022, 2, 10]]}, 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['10.1183/13993003.01724-2021'], 'URL': 'http://dx.doi.org/10.1183/13993003.01724-2021', 'relation': {}, 'ISSN': ['0903-1936', '1399-3003'], 'subject': ['Pulmonary and Respiratory Medicine'], 'container-title-short': 'Eur Respir J', 'published': {'date-parts': [[2021, 8, 26]]}}